

SUBJECT INDEX

A

- Acetyl-coenzyme A (CoA)
 - carbohydrate and fat metabolism during exercise, 125, 133-34
 - synthesis of fatty acids from, 523-27
- Acne
 - retinoic acid therapy for, 267
- Acyl-CoA carboxylase (ACC), 526-27
- Adenosine triphosphate (ATP), 34
- Adipocyte lipid-binding protein, 217
- Adipose tissue
 - de novo lipogenesis in, 529, 532-33
 - measuring, 532-33
 - glucose-transport proteins in, 237, 244, 247, 249
 - triglyceride stores in, 180, 191
- Adipsin, 292
- Adrenal steroid hormones
 - mineralocorticoids, 443-64 (See also Mineralocorticoids)
 - synthesis, 444-47
- Adrenocorticotrophic hormones (ACTH), 447
- Alanine, 122
- Alcoholism
 - among indigenous peoples, 429, 435
- Allergic eosinophilic gastroenteritis, 168-69
- Allergy; food (See Food allergy)
- Alzheimer's disease
 - vitamin E supplementation therapy for, 337-38
- Amino acids
 - metabolism, 192
 - parenteral nutrition for low-birth-weight infants, 477-81
- Ammonia metabolism, 192
- Amyotrophic lateral sclerosis
 - mutations affecting CuZnSOD in, 40
- Anaphylaxis, 162, 166-67
- Anaplerosis, 129
- Anemia
 - indigenous peoples dietary change and, 424
- Anencephaly, 73-74
- Angiotensin converting enzyme inhibitors, 102, 108-9

Antibiotics

- intestinal and renal peptide transport systems and, 101-4
- β -lactam, 103-4, 109-10
- peptidomimetic, 108-9
- Anticancer drugs
 - peptide transporters and, 102
- Antifolates, 501, 507-10, 512, 514, 516
- Antioxidants, 33-45, 51, 57-59, 63-69, 321-40
- atherosclerosis inhibition, 51, 57-59, 63-67
- bilirubin, 59
- carotene, 34, 4251, 57-58
- β -, 34, 42
- carotenoids, 33, 42
- defenses, 39-40
- enzymes and substrates, 40
- flavonoids, 33, 42
- metal ion sequestration, 40
- plant phenolics, 33, 42
- as pro-oxidants, 44
- prubucol, 58-59
- α -tocopherol, 34, 41-42, 57-58, 322, 327-28
- urate, 59
- vitamin C, 33, 41-42, 44-45, 51, 57, 63, 67, 321-40
- vitamin E, 4, 11, 16, 33, 41-43, 45, 51, 57, 63, 67, 321-40
- (See also under individual antioxidants)
- Appetite, 286, 290-96, 308-14
- nutrients and, 292-95
- satiation and, 285, 293-95, 308
- satiety and, 290-96, 308-14
- Arthropathy, 149-50
- Ascorbate, 59, 324 (See also Vitamin C)
- Ataxia with vitamin E deficiency (AVED), 329-31
- Atherosclerosis
 - cholesterol-lowering interventions, 354-56
- Atherosclerosis
 - dietary fat and, 60-67
 - fatty streak
 - etiology of, 52
 - foam cells, 53
 - free radicals and, 37-39, 44
 - lipid peroxidation and, 37-39
 - metal ion catalysts, 38-39, 44

- hypercholesterolemia and, 52
- β -lipoproteins and, 10
- oxidation hypothesis of, 52
- vitamin E supplementation therapy, 334-36
- Atopic dermatitis, 165, 167-69, 173

B

- Basophil histamine release, 165, 170
- Bile formation, 193
- Birth defects, 73-94
- micronutrient deficiency during periconceptual period and, 73-94
- anencephaly, 73-74
- cardiovascular defects, 91
- cleft lip/cleft palate, 91-92
- folate deficiency, 73-75, 78-80, 83-89, 93
- neural tube defects, 73-75, 78-89, 93
- urinary tract disorders, 90-91
- Blood-brain barrier
 - transcellular folate transport across, 502
- Blood-cerebrospinal fluid barrier
 - transcellular folate transport across, 502
- Bombesin
 - satiety and, 290
- Bovine lactalbumin, 164
- Bovine lactoglobulin, 164
- Bovine serum albumin, 164

C

- Caco-2, 110, 112
- Cancer, 33-34, 43, 267
- age-related oxidative stress and, 43
- lung
 - β -carotene and, 34
- retinoids and prevention of, 267
- Carbohydrate metabolism, 121-34, 189-91, 523-52
- de novo lipogenesis, 523-52 (See also De novo lipogenesis)
- Cardiac metabolism, 7-13
- congestive heart failure and, 9-10
- thiamin deficiency and, 7

- Cardiac muscle
retinoic acid and, 266
- Cardiovascular birth defects
folic acid deficiency and, 9
- Cardiovascular disease
current clinical guidelines,
357-63
indigenous peoples dietary
change and, 434-35
- Carotene, 34, 42, 51, 57-58, 261-
62, 276
 β -, 34, 42, 261-62, 276
retinoic acid formation
from, 261-62, 276
cardiovascular disease end-
points reduction with in-
take of, 57-58
- Carotenoids, 33, 42
- Casein, 163, 173
- Cataracts
vitamin E supplementation for,
337
- Catecholamines, 122
- Celiac disease, 168, 172
- Cell proliferation
folate receptors and, 513-16
- Cellular retinoic acid-binding
protein (See CRABP)
- Cellular retinol-binding protein
(See CRBP)
- Cereal grains
allergy to, 164
- Cholecystokinin
satiety and, 290
- Cholesterol, 52, 54, 349-75
coronary heart disease preven-
tion and, 349-75
cholesterol-lowering inter-
ventions, 354-56
estrogen replacement ther-
apy and, 359, 362-63
policy implementation, 371-
74
oxidation of, 54
- Choline deficiency, 4, 8-10
- Cigarette smoking cessation
de novo lipogenesis and,
545
- Cirrhosis, 139, 146-47, 149
arthropathy and, 149
hepatocellular carcinoma and,
147-48
- Cleft lip/cleft palate
folic acid deficiency and, 91-
92
- Coenzyme A, 7-8
- Coenzyme Q, 11
- Colic
food allergy and infantile, 167
- Colitis
food-induced, 167, 171
- Congenital lipid adrenal hyper-
plasia, 451-53
- Copper
low-density lipoprotein oxida-
tion and, 54
- Coronary artery disease (CAD),
52, 55-67
cellular prooxidant activity
and, 64-65
cellular resistance to fatty ac-
ids and, 65
dietary fat and, 60-67
low-density lipoprotein oxida-
tion and, 55-59, 60-64
vitamin C and vitamin E intake
and
inverse relationship be-
tween, 57
- Coronary heart disease, 349-75
cholesterol-lowering interven-
tions, 354-56
estrogen-replacement therapy
and, 359, 362-63
hypercholesterolemia and 351-
75
current clinical guidelines,
357-63
primary prevention, 349-75
surrogate and clinical en-
points, 351-52
- Cow milk
allergy to, 163-64, 166-68,
170, 173-74
anaphylaxis and, 167
- CRABP, 258, 264-67
- CRABP type 1 (CRABPI) and
type 2 (CRABPII), 205-6,
217-27, 264-65, 267
expression, 217-18
gene regulation, 218-19
ligand binding, 219-20
modulation of retinoic acid me-
tabolism, 224-26
structure, 220-24 CRBP,
CRBP type 1 (CRBPI),
and CRBP type 2
(CRBPII), 205-16, 226-
27, 264, 265, 271
expression, 207-8
gene regulation, 208-9
ligand binding, 209-10
retinoic acid synthesis, 213,
215
retinoid nutritional status and,
208
retinol esterification, 213-16
retinol transfer, 213
retinoldehyde reduction and,
213-14
retinyl ester hydrolysis, 213-15
structure, 210-13
- Cystinuria, 101
- Cytochromes P450, 34
- Cytokines
de novo lipogenesis and, 544
- Cytoplasmic retinoic acid-bind-
ing proteins (See CRABP)
- Cytoplasmic retinol-binding pro-
teins (See CRBP)
- D
- Dehydroepiandrosterone (DHEA),
453
- De novo lipogenesis, 523-52
alcoholic liver disease and, 551
biochemical pathways, 523-29
acetyl-coenzyme A (CoA),
523-27
acyl-CoA carboxylase
(ACC) and, 526-28
enzyme regulation, 527-28
gene regulation, 529
hepatic, 529, 541-52
cigarette smoking cessation
and, 545
cytokines and, 544
ethanol and, 543-44
fructose vs. glucose intake
and, 541-42
gonadal hormones and, 544-
45
glycogen storage disease
type I, 546
high-fat diets and, 541
low-fat/high-carbohydrate
diets and, 542-43
meal frequency and, 543
medium chain triglycerides
and, 546
obesity-related metabolic
disturbances and, 545
hypertriglyceridemia and, 542,
551
- macronutrient balance theory
and, 549
- measurements, 529-41
adipose tissue fatty acid
composition, 532-33
incorporation of labeled
water, 536, 540-41
indirect calorimetry, 529-32
mass isotopomer distribu-
tion analysis, 536-40
- 11-Deoxycorticosterone (DOC),
446-47
- Devazepide, 290
- Diabetes mellitus
arthropathy and, 149-50
indigenous peoples dietary
change and incidence of,
425, 430, 434
maturity onset diabetes of the
young (MODY), 243
non-insulin-dependent, 247,
249
vitamin E supplementation for,
336-37

- Dietary fat
cellular prooxidant activity
and, 64-65
cellular resistance to fatty acids and, 65
low-density lipoprotein oxidation and, 60-64
- Differentiation
retinoic acid and, 259-60, 265
embryonal carcinoma cells, 265
human leukemic cells, 265
mesodermal, 266
neuronal, 266
- DNA methylation
folate and, 75
- Docosahexaenoic acid (DHA), 63, 65
- Double-blind placebo-controlled food challenge (DBPCFC), 171, 173
- Drug absorption
food interactions and, 383-406
delayed drug absorption, 396-401
direct effect of food, 386
drug formulation, 384
no effect, 401-6
reduced drug absorption, 386-92
type and size of meal, 384
Drug-food interactions (See Drug absorption, food interactions)
- Dyslipidemias, 352-75
current clinical guidelines, 357-63
- E
- Eicosapentaenoic acid (EPA), 63, 65
- Electrolytes
parenteral nutrition for low-birthweight infants, 486-87
- Embryogenesis
CRABP- and CRABP-II expression during, 218
- Embryonic development
folic acid (See also Birth defects; Folic acid, periconceptional period)
- Endoplasmic reticulum, 113
- Energy intake
dietary fat and, 295-96
high-fat foods
overconsumption and, 308-10, 314
- Energy requirements
parenteral nutrition for low-birthweight infants, 481-82
- Estrogen-replacement therapy, 359, 362-63
- Ethanol
metabolism of, 180, 191
- Exercise, 121-34
carbohydrate metabolism during, 121-34
difference in metabolic response to, 123-25
endurance training, 126-34
glycogen sparing in, 131-34
fat metabolism during, 121-34
maximal oxygen uptake capacity, 123-25, 127
plasma glucose lactate threshold, 123-25
- Extracellular folate concentrations (EFC), 502, 509, 512-13
- F
- Familial isolate vitamin E (FIVE) deficiency, 329-32
- Fat intake, 285-314
appetite and, 286, 290-96, 308-14
high-fat foods
overconsumption and, 308-10, 314
hunger and, 292-95
obesity and, 286, 310-14
satiation and, 285, 293-95, 308
satiety and, 285, 290-96, 308-14
- Fat metabolism, 121-34
- Fatigue, 121, 126, 129
- Fatty acids
metabolism, 191
monounsaturated, 60-64, 66-67
polyunsaturated, 51, 53-54, 56-57
- Ferritin, 141-45, 151-57
liver disease and high serum concentration of, 152
reference range for serum concentration of, 151
storage iron, 141
- Fetal alcohol syndrome, 435
- Fetal malformations (See Birth defects)
- Fish oil supplements, 63-64, 67
- Flavin adenine dinucleotide (FAD), 43
- Flavonoids, 33, 42
- Folate, 73, 75-77
dietary intake, 77
dietary sources, 76-77
DNA methylation, 75
supplementation, 80-94
(See also Folate/antifolate transport; Folate receptors; Folate deficiency; Folic acid)
- Folate/antifolate transport, 501-17
anti-carcinoma drug transport, 514-16
blood-brain barrier, 502
blood-cerebrospinal fluid barrier, 502
extracellular folate concentrations (EFC) and, 502, 509, 512-13
folate receptor (FR)-mediated, 501-17
linkage of folate receptor- and reduced-folate carrier-mediated, 507-10
potocytosis, 507-8
reduced folate carrier-mediated (RFC), 501-2, 507-10
renal tubular cell, 502, 507
transplacental maternal-to-fetal transfer, 501-2, 505-7, 516
- Folate-binding proteins (FBP) (See Folate receptors)
- Folate deficiency
birth defects, 73-75, 78-80
low-birthweight infants, 505
megaloblastic anemia, 505
megaloblastosis from, 502
neural tube defects, 505
- Folate receptors, 501-17
cell proliferation and, 513-16
expression, 510-13
extracellular folate concentrations and, 512-13
regulators, 511-13
glycosyl-phosphatidylinositol (GPI) anchored, 513
ligand binding, 503-5
molecular structure, 503
- Folate transporter protein, 107
- Folic acid (PGA), 73-94
deficiency
cardiovascular defects, 91
cleft lip/cleft palate, 91-92
limb reductions, 92
neural tube defects, 80-89
urinary tract defects, 90-91
mechanism of action, 89
neural tube defects intervention studies, 80-83
neural tube defects prevention, 83-89
- Food allergy, 161-74
adverse reactions from, 162-63
prevalence, 162-63
allergic eosinophilic gastroenteritis and, 168-69, 172
allergens, 163-74

- bovine gammaglobulin, 164, 170
- bovine lactoglobulin, 164, 170
- bovine serum albumin, 164
- casein, 163
- cereal grains, 164
- chicken egg, 164, 172-73
- cow milk, 163-64, 166-68, 170, 173-74
- peanuts, 164
- profilins, 164-65
- soy, 167-68
- water-soluble glycoproteins, 163-64
- whey, 163
- anaphylaxis, 162, 166-67
- atopic dermatitis and, 165, 167-69, 173
- celiac disease and, 168
- colitis, 167, 171
- defined, 162
- diagnosis
- basophil histamine release assays, 170
 - double-blind placebo-controlled food challenge (DBPCFC), 171, 173
 - radioallergosorbent tests (RAST), 169-71
 - elimination diets for, 172-73
 - immunoglobulin E-mediated, 161-62, 164
 - infantile colic and, 167
 - malabsorption syndromes and, 167-68, 171
 - mediators, 165-66
 - pathogenesis, 165
- Food intolerance, 161-62
- defined, 162
 - types of, 162
- Free fatty acids, 121-34
- exercise and regulation of, 122-28, 131-34
 - endurance training, 126-28
 - glycogen-sparing effect of, 126, 131-34
 - lactate threshold, 123-25
 - levels of training, 123-25
 - release from adipose tissue, 123-25
- Free radicals, 33-39, 41, 54
- defined, 35
 - lipid peroxidation and, 37
 - metal ion catalysts, 38-39
 - nitric oxide, 33, 36
 - reactions of, 37-39
 - superoxide, 35-36
- G
- Galanin, 292
- Gastrointestinal tract
- influence of food on, 384-86
 - drug absorption and, 386
- Glucagon, 122, 180-81, 188, 290
- satiety and pancreatic, 290
- Gluconeogenesis, 5, 12-13, 122, 127, 179, 189-93
- alanine, 122
 - lactate, 122
 - rate-controlling enzymes of gene expression of, 193
- Glucose, 121-34
- exercise and regulation of plasma, 122-34
 - catecholamines and, 122
 - endurance training and, 126-28
 - insulin and, 122, 131
 - nutritional state, 125-26
 - training level, 123-25
- Glucose paradox, 189
- Glucose transport proteins (GLUT), 235-50
- adipose tissue, 237, 244, 247, 249
 - brain, 241-42
 - heart muscle, 244, 246, 249
 - insulin-resistance and, 245-47
 - insulin-stimulated regulation of, 244-45
 - intestinal, 243-44
 - isoforms
 - distribution, 237-38
 - functions, 238-39 - kidney, 243-44
 - liver, 242-43
 - pancreatic β -cells, 242-43, 249-50
 - skeletal muscle, 244, 246, 249
 - structure, 239-41
 - transgenic mice, 247-49
 - (See also Glucose transporters)
- Glucose transporter gene family (See Glucose transport proteins)
- Glucose transporters, 128, 130-31 (See also Glucose transport proteins)
- Glutamate synthetase, 179
- Glycogen, 4/-5, 180, 189, 121-34
- deposition
 - adrenal steroids and, 4-5 - muscle, 128-34
 - endurance training and regulation of, 126-28
 - exercise and regulation of, 128-34
 - resynthesis, 126
 - sparing effect of free fatty acids, 126, 131-34
 - supercompensation, 129-31
- Glycogen storage disease type I, 546
- Glycogenolysis, 132-34
- Glucosyl-phosphatidylinositol-anchored folate receptors (See Folate receptors)
- Guru Walla model, 533, 548-49
- H
- Hartnup disease, 101
- H⁺-coupled peptide transport, 103-12, 114
- PEPT1 and, 105-12, 114
 - PEPT2 and, 106-12, 114
- Hematopoiesis, 16
- Hemochromatosis, 139-57
- cirrhosis secondary to, 139
 - genetic, 139-57
 - genetic markers, 153-54
 - heart and, 148-49
 - hepatocellular carcinoma and, 139, 147-48, 157
 - inheritance
 - histocompatibility antigen typing, 143 - intestinal cell and, 144
 - lipid peroxidation byproducts and, 147
 - liver function and, 144-48
 - liver transplantation for, 156
 - pancreas and, 148
 - diabetes mellitus and, 148
 - parenchymal cell deposition, 140
 - phlebotomy for, 155
 - prevalence, 142-43, 154-55
 - reticuloendothelial system and, 145
 - screening, 149-50
- Hemoglobin, 141
- Hemorrhagic renal syndrome, 4, 8-9
- Hemosiderin, 141, 148-49
- Hepatic metabolism
- de novo lipogenesis, 541-52
 - (See also De novo lipogenesis)
- Hepatocellular carcinoma, 139, 147-48, 157
- cirrhosis and, 147-48
 - chronic alcoholism and, 147
 - tobacco smoking and, 147
- High-density lipoproteins (HDL), 60-61, 321, 327
- High-fat diet
- hepatic de novo lipogenesis in, 541
 - indigenous peoples dietary change to, 431, 435
- Histamine-releasing factor, 165
- Histocompatibility antigen (HLA), 139, 142-43
- HIV
- hydrogen peroxide and expression of, 37

- Homocyst(e)ine, 76, 89
 Hormones
 adrenal steroid hormones
 mineralocorticoids, 443-64
 synthesis, 44-47
 adrenocorticotrophic (ACTH), 447
 gonadal, 544-45
 HOX genes
 retinoic acid and, 266-67
 Hunger, 292-95
 Hydrogen peroxide, 36-37, 192
 HIV expression and, 37
 metabolic roles for, 37
 toxicity of, 38-39
 Hydroxylase deficiency, 454-59
 1 β -, 457-59
 17 α -, 458-59
 21-, 454-57
 3 β -Hydroxysteroid dehydrogenase, 446, 450-53
 deficiency, 453
 Hypercholesterolemia, 52, 59, 351-75
 Hypertension
 asymptomatic adults, 352
 low-renin, 459-64
 renin-angiotensin/mineralocorticoid system and, 461-62
 syndromes
 17 α -hydroxylase, 458-59
 11 β -hydroxylase deficiency, 457-58
 Hyperthyroidism, 9-10
 Hypertriglyceridemia, 542, 551
 Hypervitaminosis A, 274, 277
 Hypoglycemia, 121-22, 125-26
 Hypolipemia, 4, 8-9
 Hypoxia, 142
 I
 Immunity
 retinoic acid and, 267
 Immunoglobulin E response
 food reactions and, 161-62, 164-74
 basophil histamine release and, 165, 170
 histamine-releasing factor and, 165
 infant colic and, 167
 interferon gamma production and, 166
 radioallergosorbent tests (RAST) for, 169-71
 Inborn errors of metabolism, 27
 Incorporation of labeled water, 536, 540-41
 Indigenous peoples
 culture and dietary choice, 419-26
 cultural preference, 421
 economics, 421
 education and the media, 421-22
 non-directed dietary change of, 417-36
 alcoholism, 429, 435
 anemia, 429, 433-34
 cardiovascular disease, 434-35
 diabetes, 430, 434
 economics, 425-26
 environmental contaminants, 429
 epidemiology, 425
 fetal alcohol syndrome, 435
 gestational diabetes and, 430
 high-fat diets, 431, 435
 obesity and, 430, 434
 research, 428-32
 sedentary lifestyle, 434
 sugars, 425
 traditional food systems
 among, 418-36
 defined, 418
 dietary choice, 419-26
 dietary structure, 427-28
 diversity, 427
 indigenous food technologies, 419-20
 low heart-disease prevalence with, 425
 nutrition, 428
 protecting, 435-36
 (See also Traditional food systems)
 Inflammatory bowel disease
 oxidative stress and, 36, 43
 Insulin, 122, 131, 180, 188-89, 235, 243-50
 adipose tissue and, 237, 244, 247, 249
 glucose transport activity and, 245-50
 heart muscle and, 244, 246, 249
 skeletal muscle and, 244, 245-46, 249
 Insulinopenia, 243
 Intestine
 absorption in, 101-2, 141-42
 glucose transport proteins in, 243-44
 hemochromatosis and, 144
 iron-binding proteins in, 142
 peptide transporter system, 99-114
 absorption of antibiotics and, 101-2
 H⁺-coupled, 104-7
 PEPT1, 99, 105-12, 114
 regulation, 111-12
 Iron
 absorption, 140-43
 ferritin and, 141-43
 transferrin and, 141-43
 vitamin C and, 141
 deficiency, 140, 151, 152, 155
 dietary intake, 151-52
 excessive
 iron-loading disorders, 139-57
 (See also Hemochromatosis)
 oral intake, 152
 supplementation
 excessive, 44-45
 optimal, 44
 Ischemic heart disease
 vitamin E supplementation for, 333-34
 K
 Kidney
 glucose transport proteins in, 243-44
 (See also De novo lipogenesis)
 hemorrhagic renal syndrome, 4, 8-9
 mineralocorticoids and salt retention in, 444, 450
 peptide transporter systems in, 99-114
 absorption of antibiotics and, 101-2
 H⁺-coupled, 104-7
 PEPT2, 99, 106-12, 114
 regulation, 111-12
 Zn²⁺, Mn²⁺, and Cu²⁺ and, 105
 renal tubular cells, 502, 507
 Kupffer cells, 146-47
 L
 Lactate, 122-25
 threshold, 123-25
 Leukemias
 promyelocytic
 all-trans-retinoic acid treatment for, 267
 Linoleate, 61
 Linoleic acid, 18
 Lipid-binding proteins, 205-6
 Lipid peroxidation, 37-38, 51-55, 147
 atherogenesis and, 51-55
 free radicals and, 37-38
 hemochromatosis and byproducts of, 147
 Lipids
 parenteral nutrition for low-birthweight infants, 483-86
 Lipoproteinemia
 alpha beta-, 326
 hyp β -, 326

Lipoproteins

- high density (HDL), 321, 327
- intermediate density (IDL), 331
- low density (LDL), 321, 331, 334-36
- very low density (VLDL), 321, 327-31

Liver

- acinus, 182-98
 - biomatrix, 186, 188
 - cell-cell contacts, 186
 - zonation of gene expression in, 193-98
- amino acid and ammonia metabolism, 192
- bile formation, 193
- carbohydrate metabolism and, 189-91
- de novo lipogenesis, 529, 541-52
- alcoholic liver disease and, 551
- ethanol metabolism and, 191
- fatty acid metabolism and, 191
- functions of, 180-82
- gene expression, 179, 193-98
- glucose transport proteins in, 242-43, 249
- hemochromatosis and, 140, 144-57
 - hepatocellular carcinoma and, 147-48, 157
- Kupffer cells and, 146-47
- possible site of defect, 144-45
- transplantation for, 156
- high serum ferritin concentration in, 152
- iron concentration in, 139, 152
- metabolic zonation in, 179, 182, 184-85, 188-200
- nonparenchymal metabolism in, 182, 184-85, 199-200
- parenchymal metabolism in, 182, 184-93, 200
- RRR - α -tocopherol release and, 327-28
- vitamin E metabolism and, 327-28
- Liver cell types, 179, 182-83, 186-99
 - nonparenchymal
 - fenestrated endothelial cells, 186, 199
 - Kupffer cells, 186, 199
 - perisinusoidal (Ito) cells, 186, 199
 - pit cells, 186, 199
 - parenchymal, 182, 184-86, 188-98
- Low density lipoproteins (LDL), 51-67

oxidation of

- fish-oil supplementation and, 63-64, 57

oxidized

- atherogenesis and, 55-67, 334-36
- proatherogenic properties of, 55

Lysosomes, 112-13

M

Macronutrient balance theory, 549

Mass isotopomer distribution analysis, 536-40

Maturity onset diabetes of the young (MODY), 243

Maximal oxygen uptake capacity, 123-25, 127

Medical Research Council Vitamin Study, 81

Megaloblastosis, 502, 513

Megaloblastic anemia, 505

Menkes disease, 144-45

Methionine, 76, 89

 α -Methylgluta

- dipeptide analogues of, 102

Methylmalonic acid (MMA), 80

5 Methyl-tetrahydrofolate

- (mTHF), 76-77, 79

Mineralocorticoids, 443-64

deficiency

- salt-wasting syndromes, 444, 451-57

excess

- hypertensive syndromes, 444, 457-59
- low-renin hypertension, 459-64

human mineralocorticoid receptors, 448-50

salt and water metabolism, 444

Minerals

- parenteral nutrition for low-birth-weight infants, 486-87

Monocarboxylate transporter protein, 107

Monounsaturated fatty acids (MUFA), 60-64, 66-67

Morphogenesis

- retinoic acid and, 260, 265-66

Multivitamin supplementation

- birth defects prevention
 - neural tube defect intervention studies, 80-83
 - neural tube defect prevention, 83-89

Myelin P2 protein, 217

Myoglobin, 141

N

Native peoples (See Indigenous peoples)

Neural tube defects (NTD), 73-

- 75, 78-89, 505

anencephaly, 73-75

folate deficiency and, 73-75,

- 78-80, 93

intervention studies, 80-83

nutrition and, 78

prevention, 83-89, 93

- folate acid mechanisms of action and, 89, 93

vitamin B₁₂ and, 79-80

Nicotinamide adenine dinucleotide phosphate

- (NADPH), 37-38

Nitric oxide, 33, 36

- excess production of, 36

Nutritional anthropology (See Indigenous peoples, Traditional food systems)

O

Obesity, 10-11, 286, 310-14, 430, 434, 545

- de novo lipogenesis and, 545

indigenous peoples dietary

- change and, 430, 434

Oleate, 61

Oxidation

- low-density lipoprotein, 51-67

- copper and initiation of, 54

- coronary artery disease and, 52, 55-67

Oxidative damage, 33-45

- copper ions and, 39, 44

- iron and, 44

- free radical reactions and, 37-38

O₂ toxicity

- superoxide theory of, 34-35

- peroxidation of low-density lipoproteins, 38

Oxidative stress

- cellular resistance to dietary

- fatty acids and, 65

- disease prevention and, 43

- neurodegenerative disease pathophysiology, 45

Oxygen sensing, 179

P

Pancreas

- diabetes mellitus and, 148

- hemochromatosis and, 148

Pancreatic β -cells

- glucose transport proteins in, 242-43, 249-50

Parenteral solutions

- peptide-based, 102-3
 low osmolality of, 103
 short-chain peptides in, 102
 Parkinson's disease
 vitamin E supplementation for, 337-38
 Pellagra, 21
 PEPT1, 99, 105-12, 114
 affinity for antibiotics, 108-9
 expression in intestine and kidney, 109-10
 transport mechanisms of, 109
 PEPT2, 99, 105-12, 114
 affinity for antibiotics, 108-9
 expression in kidney, 109-10
 Peptide transport, 99-114
 absorption of antibiotics and, 101-4, 108-9
 angiotensin-converting enzyme inhibitor transport and, 102
 anticancer drug transport and, 102
 cultured cell lines, 110-11
 endoplasmic reticulum, 113
 H⁺-coupled, 104-7
 lysosomal membrane, 112-13
 PEPT1, 99, 105-12, 114
 PEPT2, 99, 106-12, 114
 regulation, 111-12
 renin inhibitor transport and, 102
 substrate specificity, 103-4
 β -lactam antibiotics and, 103-4
 Periconceptual period
 multivitamin supplementation and prevention of birth defects during, 75-94
 cardiovascular defects, 91
 cleft lip/cleft palate, 91-92
 limb reductions, 92
 neural tube disorders, 83-89
 urinary tract birth defects, 90-91
 Peripheral blood mononuclear cells, 166
 Peripheral-type benzodiazepine receptor (PBR), 452
 P450c11A5, 446, 456-57, 461
 P450c11B, 456, 458
 P450c21, 454
 P450c22 enzyme, 444-47
 Phosphoenolpyruvate carboxykinase (PEPCK), 179, 193
 Phylloquinone, 18-19, 21
 Placenta
 transcellular folate transport across, 502, 505-7, 516
 Plant phenolics, 33, 42
 flavonoids, 33, 42
 Polyunsaturated fatty acids (PUFA), 51, 53-54, 56-67, 322, 339
 Potocytosis, 507-8
 Pregnenolone, 444, 446
 Primary prevention
 clinical strategies, 350-68
 population-based strategies, 350-68
 behavioral intervention, 350
 effectiveness, 365-67
 evaluation, 363
 social marketing, 350
 trends, 363-65
 surrogate and clinical endpoints, 351-52
 Profilins, 164
 Protein-calorie malnutrition, 14-18
 reversible acquired immunodeficiency syndrome in, 17-18
 Prubucol, 58-59
 Pteroylglutamic acid (PGA) (See Folic acid)
 R
 Radioallergosorbent tests (RAST), 168-71
 Reactive nitrogen species, 33, 35-45
 nitrogen dioxide, 36
 nitric oxide, 33, 36
 toxicity of, 38-39
 Reactive oxygen intermediates, 192-93
 Reactive oxygen species, 35-45, 54, 192-93
 hydrogen peroxide, 36-37
 metabolic roles for, 37
 superoxide, 35-36
 toxicity of, 38
 Reduced-folate carrier, 501-2, 507-10
 (See also Folate/antifolate transport)
 Renal tubular cells
 transcellular folate transport across, 502, 507
 Renin/angiotensin/mineralocorticoid system, 461-62
 Reproduction
 retinoic acid and, 258-60
 Reticuloendothelial system, 145
 Retinaldehyde
 reduction of, 213-14
 Retinoic acid, 257-77
 all-trans- (tRA), 258-59, 267
 cancer prevention and treatment with, 267, 276
 differentiation and, 259-60
 formation from β -carotene, 261-62
 HOX genes and, 266-67
 immunity and, 267
 isomers of, 260-61
 morphogenesis and, 260, 265-66
 cardiac muscle, 266
 multiple effects of, 259-60
 nuclear receptors, 260, 269
 RARs, 257, 266, 269-77
 RXRs, 257, 260, 266, 269-77
 pattern formation and maturation, 258-59
 proliferative disease treatment with, 274
 sperm formation and maturation, 258-59
 synthesis, 213, 215, 264-65
 CRBP and CRBPI, 264-65
 vision and, 258-59
 Retinoic acid response elements (RARE), 266, 269-77
 β -, 272
 Retinoids
 metabolism, 205-27
 CRABPI and CRABPII and, 205-6, 217-27
 CRBP and CRBPII and, 205-16, 226-27
 synthetic, 274-77
 antiDAP-1 selective, 276
 RAR subtype, 274-75
 RXR-selective, 275-76
 Retinol (See Vitamin A)
 Retinol-binding proteins, 205-16, 226-27
 CRBP and CRBPII
 expression, 207-8
 gene regulation, 208-9
 ligand binding, 209-10
 retinaldehyde reduction and, 213-14
 retinoic acid synthesis and, 213, 215
 retinoid nutritional status and, 208
 retinol esterification and, 213-16
 retinol transfer and, 213
 retinyl ester hydrolysis and, 213-15
 structure, 210-13
 Retinopathy
 premature infants and, 34, 41, 45
 vitamin E and, 41, 45
 Retinyl ester hydrolysis, 213-15
 Rheumatoid arthritis, 36
 S
 Salt and water metabolism (See Mineralocorticoids)
 Salt-wasting syndromes, 444, 451-57

- Satiation, 285, 293-95, 308
 nutrients and, 294-95
 vs. satiety, 293-94, 308
 Satielin, 292
 Satiety, 285, 290-96, 308-14
 adipin and, 292
 bombesin and, 290
 cholecystokin and, 290
 galanin and, 292
 high-fat foods and, 293-95,
 308-10, 314
 nutrients and, 294-95
 pancreatic glycogen and, 290
 vs. satiation, 293-94, 308
 satielin and, 292
 serotonin and, 290-91
 somatostatin and, 290
 Serotonin
 satiety and, 290-91
 Skeletal muscle
 glucose transport proteins in,
 244, 245-46, 249
 Social marketing, 350
 Somatostatin
 satiety and, 290
 Soy sensitivity, 167-68
 Spermatogenesis
 retinoic acid and, 258
 Spina bifida, 73
 Steroidogenic acute regulatory
 protein (StAR), 452-53
 Steroids (See Adrenal steroid hor-
 mones, Mineralocorticoids)
 Superoxide dismutases (SODs),
 35, 40
 Superoxide radical anion, 192
 Superoxides, 35-39, 64-65, 192
 copper oxides and, 39
 generation of
 fatty acid supplementation
 and, 64-65
 reactions of, 37-38
 toxicity of, 38-39
 T
 Testosterone production
 retinoic acid and, 259
 Thiamin deficiency, 7
 Thiobarbituric acid-reactive sub-
 stances, 66
 Tocopherol, 34, 41-42, 57-58,
 321-23, 326-30
all-rac- α -, 323, 326-30
 α -, 34, 41-42, 57-58, 322,
 327-28
 liver and release of, 327-28
RRR- α -, 323, 326-30
SRR- α -, 328-30
 Tocopheral transfer protein, 321,
 328-31
 neurologic disorders from defi-
 ciency in, 329-31
 Traditional food systems
 defined, 418
 dietary choice in, 419-26
 dietary structure of, 427-28
 diversity, 427
 indigenous food technologies,
 419-20
 low diabetes prevalence, 425
 low heart disease prevalence,
 425
 loss of, 417-36
 nutrition, 428
 protecting, 435-36
 (See also Indigenous peoples)
 Transferrin, 141-43
 Triglycerides, 122-28, 180
 adipose tissue stores of, 123-25
 lipolysis of intramuscular, 123
 U
 Ubiquinone, 11, 13
 Urinary tract birth defects, 90-91
 multivitamin supplementation
 to prevent, 91
 V
 Vasopressin, 444
 Very low density lipoprotein
 (VLDL), 63, 321, 327-31
 Vitamin A (retinol)
 cancer prevention and, 267,
 276-77
 retinoic acid derivatives of
 (See Retinoic acid)
 signal transduction, 206 (See
 also CRABP; Retinol-
 binding proteins)
 Vitamin B₆, 76, 88
 Vitamin B₁₂, 76, 78-80, 88-89
 deficiency in
 low birthweight, 78
 neural tube defects, 79-80,
 88
 Vitamin C, 33, 41, 44-45, 51, 57,
 63, 67, 141, 321-40
 coronary artery disease preven-
 tion and, 57
 iron absorption and, 141
 (See also Ascorbate)
 Vitamin E, 4, 11, 16, 33, 41-43,
 45, 51, 57, 63, 67, 321-40
 absorption, 325-26
 antioxidant properties, 323-25,
 332-40
 coronary artery disease preven-
 tion and, 57
 deficiency, 322-23, 328-32
 delivery of
 liver and, 327-28
 ataxia with vitamin E defi-
 ciency (AVED), 329-
 31
 familial, isolate vitamin E
 (FIVE), 329-32
 Wilsons disease, 328
 distribution, 326-27
 metabolism, 327-28, 331-32
 liver and, 327-28
 supplementation, 332-40
 Alzheimers disease and,
 337-38
 atherosclerosis prevention,
 334-36
 cataracts prevention and, 337
 diabetes and, 336-37
 immune function and, 338
 ischemic heart disease pre-
 vention and, 333-34
 Parkinsons disease and, 337-
 38
 tocopherol transfer protein
 and, 328-31
 transport, 326-27, 331
 uptake, 331
 Vitamin K, 4, 6, 11, 13, 16-17
 mode of action, 13
 Vitamins
 parenteral nutrition for low-
 birthweight infants, 487-
 88
 W
 Whey, 163
 Wilsons disease, 144-45, 328
 X
 Xenobiotic metabolism, 181,
 192-93

